RU2014152454A - Производное никотинамида в лечении острого коронарного синдрома - Google Patents
Производное никотинамида в лечении острого коронарного синдрома Download PDFInfo
- Publication number
- RU2014152454A RU2014152454A RU2014152454A RU2014152454A RU2014152454A RU 2014152454 A RU2014152454 A RU 2014152454A RU 2014152454 A RU2014152454 A RU 2014152454A RU 2014152454 A RU2014152454 A RU 2014152454A RU 2014152454 A RU2014152454 A RU 2014152454A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- paragraphs
- cyclodextrin
- nicotinamide
- cyclopropylcarbamoyl
- Prior art date
Links
- 208000004476 Acute Coronary Syndrome Diseases 0.000 title claims abstract 17
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical class NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 24
- 150000001875 compounds Chemical class 0.000 claims abstract 18
- KKYABQBFGDZVNQ-UHFFFAOYSA-N 6-[5-[(cyclopropylamino)-oxomethyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide Chemical compound CC1=C(F)C=C(C(=O)NC2CC2)C=C1C1=CC=C(C(=O)NCC(C)(C)C)C=N1 KKYABQBFGDZVNQ-UHFFFAOYSA-N 0.000 claims abstract 9
- 235000009421 Myristica fragrans Nutrition 0.000 claims abstract 8
- 239000001115 mace Substances 0.000 claims abstract 8
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 208000007814 Unstable Angina Diseases 0.000 claims abstract 4
- 208000010125 myocardial infarction Diseases 0.000 claims abstract 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims abstract 2
- 208000000770 Non-ST Elevated Myocardial Infarction Diseases 0.000 claims abstract 2
- 208000035868 Vascular inflammations Diseases 0.000 claims abstract 2
- 230000002411 adverse Effects 0.000 claims abstract 2
- 230000007211 cardiovascular event Effects 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 239000012458 free base Substances 0.000 claims abstract 2
- 210000004165 myocardium Anatomy 0.000 claims abstract 2
- 230000000087 stabilizing effect Effects 0.000 claims abstract 2
- 229940124597 therapeutic agent Drugs 0.000 claims abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 2
- PVPBHKCSQBLDEW-ZQOBQRRWSA-N (1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol 4-hydroxybutane-1-sulfonic acid Chemical compound OCCCCS(O)(=O)=O.OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O PVPBHKCSQBLDEW-ZQOBQRRWSA-N 0.000 claims 1
- 239000001116 FEMA 4028 Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- 229960004853 betadex Drugs 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
- 208000006117 ST-elevation myocardial infarction Diseases 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261672439P | 2012-07-17 | 2012-07-17 | |
| US61/672,439 | 2012-07-17 | ||
| PCT/US2013/049703 WO2014014706A1 (en) | 2012-07-17 | 2013-07-09 | Nicotinamide derivate in the treatment of acute coronary syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014152454A true RU2014152454A (ru) | 2016-09-10 |
Family
ID=48794245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014152454A RU2014152454A (ru) | 2012-07-17 | 2013-07-09 | Производное никотинамида в лечении острого коронарного синдрома |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150209337A1 (enExample) |
| EP (1) | EP2874627A1 (enExample) |
| JP (1) | JP2015522612A (enExample) |
| KR (1) | KR20150036631A (enExample) |
| CN (1) | CN104507478A (enExample) |
| AU (1) | AU2013290577A1 (enExample) |
| BR (1) | BR112015000964A2 (enExample) |
| CA (1) | CA2879222A1 (enExample) |
| IN (1) | IN2014KN02981A (enExample) |
| RU (1) | RU2014152454A (enExample) |
| WO (1) | WO2014014706A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105358148A (zh) * | 2013-07-10 | 2016-02-24 | 葛兰素史克知识产权第二有限公司 | 用于治疗肾小球疾病的losmapimod |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| JP2021501130A (ja) | 2017-10-05 | 2021-01-14 | フルクラム セラピューティクス，インコーポレイテッド | ＤＵＸ４の発現を低減するためのｐ３８阻害剤の使用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711643D0 (en) * | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| JP4472349B2 (ja) * | 2002-02-12 | 2010-06-02 | スミスクライン ビーチャム コーポレーション | ｐ３８阻害薬として有用なニコチンアミド誘導体 |
| GB0318814D0 (en) * | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
-
2013
- 2013-07-09 IN IN2981KON2014 patent/IN2014KN02981A/en unknown
- 2013-07-09 JP JP2015523123A patent/JP2015522612A/ja active Pending
- 2013-07-09 AU AU2013290577A patent/AU2013290577A1/en not_active Abandoned
- 2013-07-09 CA CA2879222A patent/CA2879222A1/en not_active Abandoned
- 2013-07-09 US US14/414,798 patent/US20150209337A1/en not_active Abandoned
- 2013-07-09 RU RU2014152454A patent/RU2014152454A/ru not_active Application Discontinuation
- 2013-07-09 CN CN201380038150.5A patent/CN104507478A/zh active Pending
- 2013-07-09 KR KR1020157003956A patent/KR20150036631A/ko not_active Withdrawn
- 2013-07-09 WO PCT/US2013/049703 patent/WO2014014706A1/en not_active Ceased
- 2013-07-09 BR BR112015000964A patent/BR112015000964A2/pt not_active IP Right Cessation
- 2013-07-09 EP EP13737782.6A patent/EP2874627A1/en not_active Withdrawn
-
2016
- 2016-09-02 US US15/255,356 patent/US20160367542A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN104507478A (zh) | 2015-04-08 |
| US20160367542A1 (en) | 2016-12-22 |
| US20150209337A1 (en) | 2015-07-30 |
| AU2013290577A1 (en) | 2015-02-26 |
| WO2014014706A1 (en) | 2014-01-23 |
| JP2015522612A (ja) | 2015-08-06 |
| BR112015000964A2 (pt) | 2017-06-27 |
| IN2014KN02981A (enExample) | 2015-05-08 |
| EP2874627A1 (en) | 2015-05-27 |
| KR20150036631A (ko) | 2015-04-07 |
| CA2879222A1 (en) | 2014-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ehrlich et al. | Novel approaches for pharmacological management of atrial fibrillation | |
| CN102625658B (zh) | 包含普拉格雷和环糊精衍生物的药物组合物及其制备和使用方法 | |
| IL292161B1 (en) | New methylquinazolinone derivatives | |
| RU2015137785A (ru) | Фторсодержащие антагонисты интергрина | |
| WO2015034678A3 (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | |
| PE20212367A1 (es) | Rendimiento mejorado de formulaciones solidas y solubilizadas amorfas para lograr concentraciones de plasma terapeuticas | |
| RU2014152454A (ru) | Производное никотинамида в лечении острого коронарного синдрома | |
| US20230277674A1 (en) | Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists | |
| AR119974A1 (es) | Composición radiofarmacéutica concentrada, estable | |
| FI3737470T3 (fi) | 3-fenyyli-4-heksyylihappojohdannaisia GPR40-agonisteina | |
| RU2018128032A (ru) | Полимеры на основе циклодекстрина, способы, композиции и применение | |
| AR085273A1 (es) | Formulacion liquida libre de propelente que comprende una droga antimuscarinica | |
| KR20210054540A (ko) | 아네톨 트리티온 또는 이의 유도체의 사이클로덱스트린 복합체를 포함하는 약제학적 조성물 | |
| CL2021001018A1 (es) | Formulación basada en ciclodextrina de un inhibidor de bcl-2 | |
| EP3556349B1 (en) | Parenteral liquid preparation comprising carbamate compound | |
| PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
| JP5804432B2 (ja) | ガルシノール、シクロデキストリンの複合体およびその方法 | |
| Delpón et al. | Class III Antiarrhythmic Drugs | |
| JP2011502169A5 (enExample) | ||
| JPWO2021165992A5 (enExample) | ||
| WO2020219880A3 (en) | Cyclodextrin supramolecular scaffolds and uses thereof | |
| Mohamed Saleem et al. | Dronedarone in the management of atrial fibrillation | |
| JP2018527407A5 (enExample) | ||
| WO2014176567A3 (en) | Pharmaceutical compositions comprising vanoxerine and antianginal compounds, and methods of administration of the same for treating episodes of cardiac arrhythmia, maintaining normal sinus rhythm, preventing recurrence of cardiac arrhythmia, and treatment of chronic cardiac arrhythmia in mammals | |
| JP2019001733A (ja) | ペメトレキセドを含有する注射用溶液製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20160711 |